CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Lilly adds to immune drug pipeline with $2.9B Merida buyout

Positive
AI Analysis

Summary

Eli Lilly acquired Merida Biotech for $2.9 billion to add protein degradation technology targeting autoimmune disorders to its drug pipeline.

Importance:7/10
Sentiment:
0.60
M&Aautoimmuneprotein degradationpipeline expansion
Related Companies

Read the original article

Published by BioPharma Dive on August 31, 2026 3:23 PM

Read Original